Bakay, U., & İzci Duran, T. (2025). Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort. Archives of Rheumatology, 40(4), 465–473. https://doi.org/10.5152/ArchRheumatol.2025.11098